Given there are serious limitations to pharmaceutical cannabinoid medications, it’s clear that the problem lies in the insurance system that has yet to evolve alongside patients’ needs and medical science. There is a clear disconnect when insurance companies can cover synthetic cannabinoid drugs but can’t acknowledge the medicinal value of whole cannabis compounds. Then again, the issue circles back to the federal government.
The Trump administration is preparing to move cannabis from Schedule I to Schedule III of…
Based on the ruling, products that are legal federally as well as at the state…
The drug’s history of healing and experimentation stretches from ancient China to American counterculture —…
The new partnership will spotlight the stories of people still behind bars for cannabis, support…
Colombia is moving forward with a controversial plan to euthanize dozens of invasive hippos descended…
Imported hashish sustained mountain economies for centuries—until modern legalization and market economics erased it almost…